Mutual of America Capital Management LLC Buys 19,681 Shares of Annexon, Inc. (NASDAQ:ANNX)

Mutual of America Capital Management LLC grew its stake in Annexon, Inc. (NASDAQ:ANNX) by 3.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 659,254 shares of the company’s stock after acquiring an additional 19,681 shares during the period. Mutual of America Capital Management LLC’s holdings in Annexon were worth $3,903,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. GSA Capital Partners LLP increased its holdings in shares of Annexon by 10.7% in the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after purchasing an additional 3,355 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Annexon by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 259,404 shares of the company’s stock valued at $1,536,000 after buying an additional 66,792 shares during the last quarter. Creative Planning raised its position in shares of Annexon by 29.5% during the third quarter. Creative Planning now owns 34,779 shares of the company’s stock worth $206,000 after acquiring an additional 7,914 shares during the last quarter. Park Avenue Securities LLC lifted its stake in shares of Annexon by 136.2% during the third quarter. Park Avenue Securities LLC now owns 118,068 shares of the company’s stock valued at $699,000 after acquiring an additional 68,082 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Annexon by 117.8% during the third quarter. SG Americas Securities LLC now owns 32,763 shares of the company’s stock valued at $194,000 after acquiring an additional 17,723 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ANNX. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon has a consensus rating of “Buy” and an average price target of $15.80.

Insider Activity at Annexon

In other news, EVP Ted Yednock sold 5,500 shares of Annexon stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $5.64, for a total transaction of $31,020.00. Following the transaction, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at $56,400. This trade represents a 35.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 20,908 shares of company stock worth $135,768. 12.67% of the stock is currently owned by company insiders.

Annexon Price Performance

Shares of ANNX stock opened at $5.22 on Friday. The stock has a market cap of $556.69 million, a PE ratio of -5.10 and a beta of 1.23. The stock has a 50-day moving average of $6.86 and a 200-day moving average of $5.94. Annexon, Inc. has a one year low of $2.27 and a one year high of $8.40.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.